QSAM Biosciences (DB:2Q20) - Stock Price, News & Analysis

2Q20 Stock Overview

QSAM Biosciences, Inc. engages in developing various nuclear medicines for the treatment of cancer. More details

2Q20 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Risk Analysis

Shareholders have been substantially diluted in the past year

Has less than 1 year of cash runway

Earnings have declined by 28.5% per year over past 5 years

Makes less than USD$1m in revenue ($0)

+ 1 more risk

QSAM Biosciences, Inc. Competitors

4SC

DB:VSC

€51.9m

Medigene

XTRA:MDG1

€20.6m

2invest

XTRA:2INV

€63.2m

Heidelberg Pharma

XTRA:HPHA

€106.7m

Price History & Performance

Summary of all time highs, changes and price drops for QSAM Biosciences
Historical stock prices
Current Share Price	US$7.00
52 Week High	US$7.46
52 Week Low	US$6.38
Beta	1.81
11 Month Change	8.19%
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	10.24%

Recent updates

Shareholder Returns

	2Q20	DE Biotechs	DE Market
7D	-2.9%	0.8%	0.8%
1Y	n/a	-18.3%	8.6%

Return vs Industry: Insufficient data to determine how 2Q20 performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how 2Q20 performed against the German Market.

Price Volatility

Is 2Q20's price volatile compared to industry and market?
2Q20 volatility
2Q20 Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.5%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: 2Q20 has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine 2Q20's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2004	5	Doug Baum	www.qsambio.com

QSAM Biosciences, Inc. engages in developing various nuclear medicines for the treatment of cancer. The company is involved in the development of CycloSam (Samaium-153 DOTMP), a clinical-stage bone targeting radiopharmaceutical. It has a license agreement with IGL Pharma, Inc. The company was formerly known as Q2Earth, Inc. and changed its name to QSAM Biosciences, Inc. in September 2020.

QSAM Biosciences, Inc. Fundamentals Summary

How do QSAM Biosciences's earnings and revenue compare to its market cap?
2Q20 fundamental statistics
Market cap	€34.35m
Earnings (TTM)	-€4.81m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-7.1x

P/E Ratio

Is 2Q20 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2Q20 income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$5.16m
Earnings	-US$5.16m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-1.16
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	1.1%

How did 2Q20 perform over the long term?

See historical performance and comparison

QSAM Biosciences DB:2Q20 Stock Report